Agenus, Inc. (AGEN)
8.24
0.00 (0.00%)
USD |
NASDAQ |
Sep 04, 16:00
8.25
+0.01
(+0.12%)
After-Hours: 20:00
Agenus Research and Development Expense (Quarterly) : 14.76M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 14.76M |
| March 31, 2026 | 11.82M |
| December 31, 2025 | 7.511M |
| September 30, 2025 | 23.60M |
| June 30, 2025 | 26.71M |
| March 31, 2025 | 21.52M |
| December 31, 2024 | 33.78M |
| September 30, 2024 | 41.06M |
| June 30, 2024 | 36.77M |
| March 31, 2024 | 43.92M |
| December 31, 2023 | 66.72M |
| September 30, 2023 | 51.44M |
| June 30, 2023 | 59.28M |
| March 31, 2023 | 57.12M |
| December 31, 2022 | 53.28M |
| September 30, 2022 | 46.01M |
| June 30, 2022 | 44.96M |
| March 31, 2022 | 42.44M |
| December 31, 2021 | 53.49M |
| September 30, 2021 | 42.94M |
| June 30, 2021 | 45.51M |
| March 31, 2021 | 36.68M |
| December 31, 2020 | 35.57M |
| September 30, 2020 | 32.13M |
| June 30, 2020 | 38.55M |
| Date | Value |
|---|---|
| March 31, 2020 | 36.36M |
| December 31, 2019 | 36.83M |
| September 30, 2019 | 46.13M |
| June 30, 2019 | 45.24M |
| March 31, 2019 | 40.13M |
| December 31, 2018 | 36.03M |
| September 30, 2018 | 29.85M |
| June 30, 2018 | 29.27M |
| March 31, 2018 | 29.44M |
| December 31, 2017 | 31.87M |
| September 30, 2017 | 25.79M |
| June 30, 2017 | 25.82M |
| March 31, 2017 | 32.64M |
| December 31, 2016 | 25.98M |
| September 30, 2016 | 21.59M |
| June 30, 2016 | 22.36M |
| March 31, 2016 | 25.04M |
| December 31, 2015 | 17.95M |
| September 30, 2015 | 18.50M |
| June 30, 2015 | 24.77M |
| March 31, 2015 | 9.220M |
| December 31, 2014 | 7.369M |
| September 30, 2014 | 5.285M |
| June 30, 2014 | 5.223M |
| March 31, 2014 | 4.472M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Novavax, Inc. | 67.79M |
| Amgen, Inc. | 1.868B |
| Anika Therapeutics, Inc. | 7.341M |
| BioCryst Pharmaceuticals, Inc. | 51.46M |
| Imunon, Inc. | 1.465M |